


# Advanced Human iPSC-derived Models for Translational Drug Discovery: 3D Spheroids and Microphysiological Systems

Amr Othman, Rebecca Fiene, David Majewski, Kirk Twaroski, Ravi Vaidyanathan, Scott Schachtele, Simon Hilcove, and Coby Carlson


FUJIFILM Cellular Dynamics, Inc., Madison, WI USA

**FUJIFILM**  
FUJIFILM Cellular Dynamics

## OVERVIEW: Drug Development should be Human-centered



In 2022, the **FDA Modernization Act 2.0** ended the long-standing mandate that required drugs to be tested on animals before they are tested in humans. This change also authorized the use of alternative technologies to reduce the reliance on animal testing. These accepted options can be grouped into four different categories: (1) cell-based assays, which include human induced pluripotent stem cells (iPSC); (2) 3D organoids & spheroids; (3) “organ chips”; and (4) computer models, which covers AI, machine learning, and bio-simulation. This poster will focus on the combination of iPSC-derived cell types as 3D spheroids or in **organ-on-a-chip** (OoC) systems.





**Human iPSC-derived cell types** are a promising new alternative to animal models since they offer more physiological relevance, meaningful drug responses, and opportunities for “disease-in-a-dish” studies. When highly specialized cell types generated via human iPSC technology (such as **iCell® products**) are paired with cutting-edge organ-on-a-chip technologies, this approach is gaining increased traction as the best hope for improving the pre-clinical pipeline for new therapeutics.

## Combine with Numerous Commercially Available Platforms




The development of **3D spheroids/organoids** and **OoC systems** has revolutionized in vitro research, offering dynamic, physiologically-relevant platforms that enable the creation of multi-cellular models which closely mimic the structure and function of native human organs. A critical requirement of such systems as they evolve and improve the scalability, complexity, and throughput, is that they maintain consistency. There are now many providers with commercially available options for organ-on-a-chip device technology and spheroid-forming ultra-low attachment (ULA) plates. Our mission is to support the integration of iPSC-derived cell types into these different platforms to reshape research across neuroscience and broader biomedical fields with the goal of bridging the gap between results from pre-clinical studies and positive clinical outcomes.


## Assess Cardiovascular Risk and Immune-related Toxicity on MEA





**Figure 2.** Beyond the “conventional” MEA assay featuring iPSC-CM in mono-culture, which has been accepted recently by the FDA into the IStand program, the NAMs concept pushes the idea of creating more complex & biologically relevant models. To this end, **iCell Macrophages 2.0** were co-cultured with iCell CM2 on MEA to evaluate the impact of an immune response on cardiac activity. **(A)** Brightfield image of CM2 on an MEA with red arrows pointing to iCell Mac 2.0; **(B)** fluorescent image with CM2 marker cTNT staining in green and Mac marker CD68 in magenta; **(C)** Bottom row of heat map (8<sup>th</sup> of 8) shows presence of Mac results in increased Sodium (Na) Spike Amplitude. **(D)** After LPS stim for >24 h, CM2/Mac co-cultures have longer and more irregular Beat Periods, altered repolarization, and detection of arrhythmias; Similar responses are **not** seen in CM2 mono-culture or unstim co-culture control wells (data not shown). Studies are ongoing to further understand the mechanism of action leading to these observations.




## Interrogate Blood-Brain Barrier Dynamics with 96-well TEER Assays



## Enhance Neuronal Phenotypes on Organ Chips



## Assemble your own iCell Neurospheres... with Microglia



## Summary

The translatability of animal models to human clinical outcomes remains a significant challenge in drug discovery, motivating the shift toward biologically relevant human cell-based platforms. iCell products from FUJIFILM Cellular Dynamics were used across diverse NAM platforms, highlighting their scalability, high purity, batch-to-batch reproducibility, and consistent in vitro phenotypes. Our results confirm that commercial iPSC-derived cell types can successfully generate complex, human-relevant tissues compatible with MPS, OoC, and 3D culture formats, improving the physiological relevance of in vitro drug testing. This work underscores the transformative potential of iPSC-based models and NAMs to craft a more human-centered process in drug discovery workflow pipelines.